Skip to main content
    C

    Contineum Therapeutics, Inc. Class A Common Stock (CTNM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.52
    +0.71 (+8.06%)

    Market Cap: $345.93M

    Last updated: Nov 06, 2026 at 4:04 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    45%(5/11)
    Avg Surprise
    -18.77%

    Upcoming Estimates

    Period ending Dec 31, 2026
    EPS Consensus$-0.26
    Range$-0.42 - $-0.09
    7 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    6 analysts
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$-0.26$-0.42 - $-0.09--7--
    Sep 26
    Reported Nov 3
    		$-0.49$-0.45$-0.51 - $-0.40-8.89%Miss7
    3
    3
    30d
    		-8.9%
    Jun 26
    Reported Jul 30
    		$-0.40$-0.46$-0.51 - $-0.38+13.04%Beat7
    7
    0
    30d
    		+35.5%
    Mar 26
    Reported May 5
    		$-0.39$-0.53$-0.61 - $-0.46+26.42%Beat7
    1
    2
    30d
    		+37.1%
    Dec 25
    Reported Mar 5
    		$-0.49$-0.65$-0.86 - $0.11+24.62%Beat7
    2
    0
    30d
    		+12.5%
    Sep 25
    Reported Oct 30
    		$-0.45$-0.46$-0.70 - $0.40+2.17%Beat7
    4
    1
    30d
    		-12.5%
    Jun 25
    Reported Aug 5
    		$-0.62$-0.41$-0.69 - $0.42-51.22%Miss6
    1
    4
    30d
    		-59.0%
    Mar 25
    Reported May 14
    		$-0.62$-0.57$-0.61 - $-0.51-8.77%Miss5
    No revisions (30d)
    		+82.5%
    Dec 24
    Reported Mar 6
    		$-0.56$-0.43$-0.50 - $-0.37-30.23%Miss4
    2
    1
    30d
    		+61.1%
    Sep 24
    Reported Nov 6
    		$-0.40$-0.42$-0.43 - $-0.35+4.76%Beat4
    No revisions (30d)
    		-
    Jun 24
    Reported Aug 13
    		$-0.39$-0.35--11.43%Miss---
    Mar 24
    Reported May 16
    		$-3.55$-1.33--166.92%Miss---
    Dec 23
    Reported Feb 28
    		$-1.44$0.00-N/AMiss---

    Key Metrics

    Valuation
    P/E Ratio-5.38EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-29.80%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest Coverage90.25x
    Current Ratio31.11xQuick Ratio31.11x
    Trading Statistics
    Beta1.07Avg Volume1.26M
    52-Week High$17.7952-Week Low$6.72

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$9.24
    SMA 20$8.67
    SMA 50$11.95
    SMA 200$13.49
    EMA 10$9.28
    EMA 20$9.58
    EMA 50$11.17
    EMA 200$12.44

    MACD

    Line: -0.64Signal: -0.93Hist: 0.29

    ADX

    ADX: 28.5+DI: 19.1-DI: 26.9

    Aroon & PSAR

    Aroon Up20.0
    Aroon Down44.0
    PSAR$7.76

    Bollinger Bands

    Upper Band$10.17
    Lower Band$7.17
    %B Position3468%(Upper)
    Band Width0.78

    RSI (14-Day)

    Neutral
    46.1

    Momentum Oscillators

    Stoch %K72.7
    Stoch %D80.2
    Williams %R-25.2
    ROC (10d)14.6%
    Momentum1.21
    CCI (20d)62.0
    MFI (14d)75.4

    Volatility Measures

    ATR (14d)$0.93(9.7%)
    StdDev (20d)0.75
    Hist Vol159.1%(High)

    Volume Flow

    VWAP$9.30
    OBV11.7M
    AD Line-5.4M
    CMF (20d)-0.284

    Volume Metrics

    Avg Vol (20d)1.3M
    Vol Ratio0.3x(Low)
    VWMA (20d)$8.48

    Pivot Points

    R3$10.74
    R2$10.29
    R1$9.55
    Pivot Point$9.10
    S1$8.36
    S2$7.91
    S3$7.17

    Advanced Oscillators

    TSI-19.70
    Ultimate Osc49.9
    KST-225.23

    Financial Data

    QuarterSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total Revenue$0$0$0$0$0$0$0$242,000$0$0$0$0
    Cost of Revenue$0$0$0$85,000$0$0$0$121,000$0$0$0$37,000
    Gross Profit$0$0$0$-85,000$0$0$0$121,000$0$0$0$-37,000
    Operating Expenses$20.97M$17.43M$16.90M$17.11M$14.93M$17.90M$18.11M$17.05M$12.97M$10.94M$9.93M$9.68M
    R&D$15.98M$12.70M$11.65M$12.76M$10.99M$14.06M$13.71M$13.02M$9.73M$7.90M$7.78M$8.01M
    SG&A$4.98M$4.73M$5.26M$4.36M$3.94M$3.84M$4.40M$4.03M$3.25M$3.04M$2.15M$1.66M
    Operating Income$-20,966,000$-17,428,000$-16,904,000$-17,115,000$-14,932,000$-17,902,000$-18,110,000$-17,046,000$-12,974,000$-10,944,000$-9,930,000$-9,676,000
    Interest Income$2.36M$2.34M$2.50M$2.01M$1.96M$2.03M$2.25M$2.53M$2.74M$2.00M$1.64M$1.79M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-18,697,000$-15,154,000$-14,456,000$-15,156,000$-12,792,000$-16,040,000$-15,990,000$-14,565,000$-10,267,000$-9,009,000$-8,417,000$-7,930,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$-161,000
    Net Income$-18,697,000$-15,154,000$-14,456,000$-15,156,000$-12,792,000$-16,040,000$-15,990,000$-14,565,000$-10,267,000$-9,009,000$-8,417,000$-7,769,000
    EBITDA$-20,311,000$-18,213,000$-17,273,000$-17,184,000$-14,664,000$-18,397,000$-18,447,000$-18,082,000$-13,729,000$-12,019,000$-11,015,000$-10,882,000
    EBIT$-21,059,000$-17,496,000$-16,961,000$-17,166,000$-14,749,000$-18,069,000$-18,240,000$-17,092,000$-13,008,000$-11,010,000$-10,053,000$-9,720,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CTNM

    News

    Johnson & Johnson reports a passive stake in Contineum Therapeutics (CTNM).

    Johnson & Johnson Innovation-JJDC, Inc. and Johnson & Johnson have reported a beneficial ownership of 1,979,173 shares, or 5.6%, of Contineum Therapeutics...

    Stock Titan•11/6/26•Neutral

    A treatment developer believes $244.5 million can fund planned work through mid-2029

    Contineum Therapeutics reported its third-quarter 2026 financial results, with a net loss widening to $18.7 million. The company, focused on inflammatory and fibrotic diseases, confirmed it has $244.5 million in cash...

    Stock Titan•11/4/26•Neutral

    Form 8K Contineum Therapeutics Inc For: 3 November By Investing.com

    This article announces that Contineum Therapeutics Inc. filed a Form 8K on November 3, 2026. The filing is available through Investing.com and relates to the company's financial and operational disclosures. The article...

    Investing.com Canada•11/3/26•Neutral

    Contineum Therapeutics Reports Third-Quarter 2026 Financial Results

    Contineum Therapeutics reported its third-quarter 2026 financial results, highlighting a cash position of $244.5 million...

    Yahoo Finance Australia•11/3/26•Somewhat-Bullish

    A passive stake in Contineum Therapeutics (CTNM) includes 445,000 shares tied to exercisable options.

    Squadron Master Fund LP, Squadron Capital Management LLC, Matthew Sesterhenn, and William Blank have reported a beneficial ownership of approximately 5.1% in Contineum Therapeutics (CTNM). This stake...

    Stock Titan•10/28/26•Neutral

    CTNM Valuation and Fair Value

    P/E
    -5.4x
    P/B
    1.5x
    See GNG's fair value

    CTNM Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -29.8%

    CTNM Competitors

    CompanyTicker
    Rezolute IncRZLT
    Viemed Healthcare IncVMD
    Zura Bio Limited Class A Ordinary SharesZURA
    Orchestra BioMed Holdings Inc.OBIO
    Orthofix Medical IncOFIX
    Semler Scientific IncSMLR
    Fennec Pharmaceuticals IncFENC
    Opus Genetics, Inc.IRD

    Sector: Healthcare

    CTNM Analyst Ratings

    Consensus
    Buy
    Analysts
    8
    Strong Buy
    1
    Buy
    5
    Hold
    2
    Sell
    0
    Strong Sell
    0

    CTNM Bull Case vs Bear Case

    Bull case

    • 75.0% of CTNM's analyst ratings are Buy or Strong Buy.

    CTNM Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -4.1%
    EPS estimate (fiscal period ending Dec 31, 2026)
    $-0.26

    CTNM Earnings Date

    CTNM reports Mar 3, 2027, after the close. The date is estimated.

    CTNM ETF Holders

    GNG tracks 7 ETFs that hold CTNM. The largest weights:

    1. State Street SPDR S&P Pharmaceuticals ETF (XPH), 0.45% of the fund
    2. iShares Biotechnology ETF (IBB), 0.02% of the fund
    3. Vanguard Total Stock Market Index Fund Admiral Shares (VTSAX), <0.01% of the fund
    4. Dimensional U.S. Core Equity 2 ETF (DFAC), <0.01% of the fund
    5. Schwab U.S. Broad Market ETF (SCHB), <0.01% of the fund
    Open the ETF Stock Exposure tool for CTNM

    Frequently Asked Questions About CTNM

    When does CTNM report earnings?

    Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is expected to report earnings on Mar 3, 2027.

    Does CTNM pay dividends?

    Contineum Therapeutics, Inc. Class A Common Stock (CTNM) does not currently pay a regular dividend.

    What is CTNM's market cap?

    Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has a market capitalization of $345.93M with a current stock price of $9.52.

    Related stocks

    Sector: Healthcare

    All stocks starting with C

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In